Newron Pharmaceuticals SpA (FRA:NP5) ROCE %: -360.38% (As of Dec. 2025)


FRA:NP5 Newron Pharmaceuticals SpA FRA:NP5
65 GF Score
Price €13.35
GF Value €13.83
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA ROCE %?

Newron Pharmaceuticals SpA FRA:NP5 +4.30% 65 ROCE % is -360.38% as of Dec. 2025. GuruFocus rates FRA:NP5 with a GF Score™ of 65/100 and a GF Value™ of €13.83 (Fairly Valued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Newron Pharmaceuticals SpA's annualized ROCE % for the quarter that ended in Dec. 2025 was -360.38%.

Newron Pharmaceuticals SpA  (FRA:NP5) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Newron Pharmaceuticals SpA ROCE % Related Terms

Newron Pharmaceuticals SpA ROCE % Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA ROCE % Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.26 -34.25 -82.71 137.90 -52.47

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -243.97 -178.52 220.88 14.05 -360.38
FRA:NP5
65GF Score
Newron Pharmaceuticals SpA FRA:NP5
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA ROCE % Calculation

Newron Pharmaceuticals SpA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-7.956/( ( (63.908 - 23.506) + (40.055 - 50.131) )/ 2 )
=-7.956/( (40.402+-10.076)/ 2 )
=-7.956/15.163
=-52.47 %

Newron Pharmaceuticals SpA's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-20.248/( ( (61.394 - 40.081) + (40.055 - 50.131) )/ 2 )
=-20.248/( ( 21.313 + -10.076 )/ 2 )
=-20.248/5.6185
=-360.38 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -360.38% mean?
Newron Pharmaceuticals SpA (FRA:NP5) has a ROCE % of -360.38% as of Dec. 2025.
Is Newron Pharmaceuticals SpA's ROCE % too high?
Newron Pharmaceuticals SpA's current ROCE % is -360.38%. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's ROCE % compare to VRTX and REGN?
Newron Pharmaceuticals SpA's ROCE % of -360.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Newron Pharmaceuticals SpA's current ROCE % is -360.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (FRA:NP5) is currently considered Fairly Valued. The stock's GF Value™ is €13.83, compared to a current price of €13.35 — trading 3.5% below its estimated fair value. The current ROCE % is -360.38%. Newron Pharmaceuticals SpA's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (FRA:NP5), the current ROCE % is -360.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €13.35 is trading 3.5% below its estimated GF Value™ of €13.83. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for FRA:NP5:

  • ROCE %: -360.38%
  • GF Value™: €13.83 vs. price of €13.35 (3.5% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
65GF Score

Get the complete analysis for FRA:NP5

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.35
Price
€13.83
GF Value